Pharmaceutical Companies Embrace AI in Drug Discovery
- Pharmaceutical giants are strategically embracing artificial Intelligence (AI) and prioritizing upskilling initiatives to enhance productivity and innovation.
- Johnson & Johnson is pioneering a new concept of the "bilingual" employee.
- Jim Swanson, the chief data officer of J&J, emphasized the importance of this dual proficiency: There are so manny ways we've been using AI, but to do that...
AI Revolution in Pharmaceuticals: Upskilling for the Future
Table of Contents
- AI Revolution in Pharmaceuticals: Upskilling for the Future
- AI Revolution in Pharmaceuticals: Upskilling for the Future – Q&A
- Table of contents
- What is the AI Revolution in the Pharmaceutical Industry?
- Why is AI upskilling important in the pharmaceutical industry?
- How are pharmaceutical companies training employees in AI?
- What is Johnson & Johnson’s approach to AI training?
- What is Merck’s AI strategy?
- How is AI benefiting smaller pharmaceutical companies?
- What is Eli Lilly’s approach to generative AI?
- How does generative AI impact drug development?
- What are the potential cost savings from AI in drug development?
- What skills are necessary for pharmaceutical employees in the age of AI?
- How are companies ensuring data security while using AI tools?
- What is the future of AI in pharmaceuticals?
- Summary Table: AI Initiatives in Pharmaceutical Companies
Pharmaceutical giants are strategically embracing artificial Intelligence (AI) and prioritizing upskilling initiatives to enhance productivity and innovation. Companies such as Johnson & Johnson (J&J), Merck, and Eli Lilly are investing in training programs to equip their employees with the skills needed to leverage generative AI effectively.
The Rise of the Bilingual Employee in Pharma
Johnson & Johnson is pioneering a new concept of the “bilingual” employee. This doesn’t refer to language skills, but rather proficiency in both core job functions (such as research, supply chain, and finance) and AI technology.
Jim Swanson, the chief data officer of J&J, emphasized the importance of this dual proficiency: There are so manny ways we’ve been using AI, but to do that effectively, we had to really create a curriculum and a mindset around upskilling.
To that end, J&J has trained over 56,000 of its 138,000 employees in generative AI. This training is mandatory before employees can utilize the technology, focusing on skills like summarization and prompt engineering. Furthermore, a digital boot camp covering AI, augmented reality, and automation has provided over 37,000 cumulative hours of training to more than 14,000 employees.
Transformative Potential of Generative AI
generative AI holds immense potential for transforming various aspects of the pharmaceutical industry.It promises to accelerate drug development by more quickly identifying compounds for new treatments and vaccines, streamline regulatory compliance, optimize patient selection for clinical trials, and improve drug marketing strategies.
Deborah Golden, Deloitte’s US chief innovation officer, highlights the shifting talent requirements in the pharmaceutical industry: When you think about how AI is shifting the balance and the talent requirements, you really need to be able to speak both the language of biology and AI models.
How AI is Reshaping Drug Development
Generative AI is projected to save the pharmaceutical industry tens of billions of dollars annually by boosting productivity in drug development.
J&J, a major player in the pharmaceutical sector, has been utilizing traditional AI for nearly a decade. Applications include AI-enabled software tools that guide surgeons, accelerate drug finding, and enhance inventory management.
In 2023,J&J conducted a six-week digital immersion program focused on AI and data science,with over 2,500 employees participating. The company plans to expand this program further in 2025.
Swanson emphasized the importance of fostering a culture that promotes technological literacy: We’ve been around 135 years. We’ve had to reinvent ourselves multiple times to stay relevant and current.
Merck’s AI Initiatives
Merck has invested in developing a proprietary platform called GPTeal, providing employees with secure access to large language models like OpenAI’s ChatGPT, Meta’s Llama, and Anthropic’s Claude.This ensures company data remains protected.
Employees are leveraging generative AI for various tasks, including drafting emails and memos. Merck’s ambitions extend to higher-impact applications.
Ron Kim, a senior vice president and the chief technology officer of Merck, stated: Now, the journey is clearly to identify, implement, track, and measure use cases that have a dramatic impact on our business.
Generative AI allows Merck’s employees to focus on more strategic tasks.For instance, it assists in drafting regulatory documents for health authorities, freeing up scientists’ time. we felt like some of our scientists were taking time being copyeditors, That’s not what they trained for,
Kim said.
Over 50,000 Merck employees are actively using GPTeal, supported by self-serve digital training courses, monthly webcasts, and boot camps for software developers.
AI’s Appeal to Companies of All Sizes
Dr.Daniel Stevens, the chief medical officer at Blue Earth Therapeutics, highlights AI’s appeal to smaller companies. As a startup founded in 2021, Blue Earth sees AI as a means to achieve efficiency goals.
The application of artificial intelligence is of interest, because it may help us with some of our efficiency goals,
Stevens said.
Blue Earth, with just 20 full-time employees, plans to utilize online courses and AI certifications from external vendors for future AI training.
Eli Lilly’s Proactive Approach to AI
Eli Lilly has embraced generative AI to support research and development, generate documentation for clinical trials, and create materials for regulatory submissions.
Diogo Rau, the chief information and digital officer at Eli Lilly, noted that the company took a different approach compared to others that restricted employee use of chatbots: We went in the exact opposite direction.
Eli Lilly encouraged its workforce to use ChatGPT without exposing sensitive company information. We told everybody you need to use it, you need to start bringing ChatGPT into your work, Don’t put anything in there that you don’t want to get out,
said Rau.
The company also organized an ”AI Games” competition to boost interest and encouraged employees to use generative AI for year-end reviews in 2024. In 2025, Eli Lilly will require all senior leaders and managers to obtain an AI certification.
we’ve got a workforce that is embracing AI,
Rau said, noting the enthusiasm among employees in applying AI to their daily tasks.
AI Revolution in Pharmaceuticals: Upskilling for the Future – Q&A
Table of contents
- What is the AI Revolution in the Pharmaceutical Industry?
- Why is AI upskilling important in the pharmaceutical industry?
- How are pharmaceutical companies training employees in AI?
- What is Johnson & Johnson’s approach to AI training?
- What is Merck’s AI strategy?
- How is AI benefiting smaller pharmaceutical companies?
- What is Eli Lilly’s approach to generative AI?
- How does generative AI impact drug development?
- What are the potential cost savings from AI in drug development?
- What skills are necessary for pharmaceutical employees in the age of AI?
- How are companies ensuring data security while using AI tools?
- What is the future of AI in pharmaceuticals?
What is the AI Revolution in the Pharmaceutical Industry?
The AI revolution in the pharmaceutical industry refers to the strategic integration of artificial intelligence (AI) technologies to enhance productivity, innovation, and efficiency across various sectors such as drug development, regulatory compliance, and marketing. this includes leveraging generative AI to accelerate research,streamline processes,and optimize resource allocation.
Why is AI upskilling important in the pharmaceutical industry?
AI upskilling is important because it equips employees with the necessary skills to effectively use AI tools and technologies, fostering innovation and maintaining a competitive edge. As Deborah Golden, Deloitte’s U.S.chief innovation officer, noted, there’s a growing need for professionals who can understand and apply both biological sciences and AI models.
How are pharmaceutical companies training employees in AI?
Pharmaceutical companies train employees in AI through various initiatives, including:
Curriculum Development: Creating structured learning paths focused on AI skills.
Digital Boot Camps: Providing intensive training on AI, augmented reality, and automation.
Self-Serve Digital Courses: Offering online courses for employees to learn at their own pace.
Webcasts & Boot Camps: Hosting regular webcasts and boot camps for software developers.
AI Certification Programs: requiring senior leaders and managers to obtain AI certifications.
What is Johnson & Johnson’s approach to AI training?
Johnson & Johnson (J&J) is pioneering the concept of the “bilingual” employee, proficient in both their core job functions and AI technology. Key elements of their approach include:
Mandatory Training: Over 56,000 of its 138,000 employees have been trained in generative AI before utilizing it.
Focus on Skills: Training emphasizes skills like summarization and prompt engineering.
Digital Immersion Programs: A six-week digital immersion program focused on AI and data science with over 2,500 participants in 2023, planning to expand in 2025.
What is Merck’s AI strategy?
Merck’s AI strategy centers around providing secure AI access and promoting strategic AI application. Key components include:
Proprietary platform (GPTeal): Developed to give employees secure access to large language models like chatgpt, Llama, and Claude.
Employee Empowerment: Encouraging employees to use generative AI for tasks such as drafting emails and regulatory documents.
Training and Support: Offering self-serve digital training courses, monthly webcasts, and boot camps.
How is AI benefiting smaller pharmaceutical companies?
AI offers smaller companies the ability to achieve efficiency goals and compete more effectively. for example, Blue Earth Therapeutics, a startup founded in 2021, uses online courses and AI certifications from external vendors for AI training, helping them streamline operations.
What is Eli Lilly’s approach to generative AI?
Eli Lilly has proactively embraced generative AI, focusing on:
Encouraging Use: Encouraging its workforce to use ChatGPT without exposing sensitive company information.
AI Games: Organizing an “AI Games” competition to boost interest and adoption.
AI Certification: Requiring all senior leaders and managers to obtain an AI certification by 2025.
How does generative AI impact drug development?
Generative AI can considerably impact drug development by:
Accelerating Identification: More quickly identifying compounds for new treatments and vaccines.
Streamlining Compliance: helping to streamline regulatory compliance processes.
Optimizing Patient Selection: Improving patient selection for clinical trials.
Enhancing Marketing: Improving drug marketing strategies.
What are the potential cost savings from AI in drug development?
Generative AI is projected to save the pharmaceutical industry tens of billions of dollars annually by boosting productivity and streamlining processes in drug development.
What skills are necessary for pharmaceutical employees in the age of AI?
Pharmaceutical employees must develop a dual proficiency:
Domain Knowledge: Strong expertise in core job functions (research, supply chain, finance, etc.).
AI Technology Skills: Proficiency in using AI tools, understanding AI models, and prompt engineering.
How are companies ensuring data security while using AI tools?
Companies like Merck are ensuring data security by:
Proprietary Platforms: Developing internal platforms that allow access to large language models without exposing company data.
Clear Guidelines: Providing use guidelines to avoid the exposure of confidential information.
What is the future of AI in pharmaceuticals?
The future of AI in pharmaceuticals involves:
increased Adoption: More widespread use of AI across all company sizes.
Enhanced Productivity: Continued improvements in productivity and efficiency.
Focus on Upskilling: Greater emphasis on training and upskilling initiatives.
Strategic Integration: Deeper integration of AI into core business processes and decision-making.
Summary Table: AI Initiatives in Pharmaceutical Companies
| Company | AI Initiative | Key Focus |
| —————– | ————————————————— | ————————————————————- |
| Johnson & Johnson | “Bilingual” Employee Program | Proficiency in core functions and AI |
| Merck | Proprietary Platform (GPTeal) | Secure AI access, employee empowerment |
| Eli Lilly | Encouraged ChatGPT Use, “AI Games,” Certification | Proactive AI adoption, company-wide AI fluency |
| Blue Earth Therapeutics | Utilizing Online courses and AI certifications from external vendors | Achieving efficiencies for startups |